Lartruvo (olaratumab)

The most common first-line treatment was doxorubicin with olaratumab (23.5%). Median TTNT was 3.9 months for the full cohort and 4.8 months for the MDM2-amplified, TP53 WT subgroup. The descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options.

P1, N=50, Recruiting, Telix Pharmaceuticals (Innovations) Pty Ltd | Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Oct 2024 | Trial primary completion date: Dec 2025 --> Mar 2026

P1, N=41, Completed, Eli Lilly and Company | Phase classification: P1a/1b --> P1

P3, N=509, Completed, Eli Lilly and Company | Active, not recruiting --> Completed

P1, N=50, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Ltd

P3, N=509, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2024 --> Jul 2024

Antitumor activity was observed in some patients in DEC, combination was well tolerated with manageable safety profile. Further studies are warranted to evaluate efficacy/mechanistic impact of platelet-derived growth factor receptors inhibitor with immune checkpoint modulator coadministration.

The most common 1L treatment was doxorubicin (doxo) with olaratumab (23.5%), followed by gemcitabine and cisplatin (15.7%)...In 2L, eribulin was the most common (21.9%), followed by gemcitabine (15.6%)... Patient demographics are consistent with a 2012 report on 208 patients from 11 institutions (10 European members of the Connective Tissue Cancers Network of Excellence and Memorial Sloan Kettering Cancer Center [New York, NY]); however, median OS observed is lower than the reported 15.2 months. For those receiving 1L doxo monotherapy or in combination, rwPFS was comparable to this report and to a 2017 report on 51 patients at MD Anderson Cancer Center (Houston, TX). These results may highlight an awareness gap between academic centers and community practices for treating DDLPS.

We present the case of a 73-year-old woman with a mismatch repair deficient (MMRd) undifferentiated cardiac sarcoma, who achieved a complete and durable response with the anti-PD1 inhibitor pembrolizumab after the failure of standard treatment consisting of doxorubicin together with olaratumab. The genomic analysis of the cardiac UDS displayed several markers known to predict response to ICIs: the tumor harbored a high TMB (> 10 mutations/Mb) and a MMRd/MSI signature. Of note, inactivating mutations of both FAT1 and NOTCH2 have also been associated with ICI therapy response in epithelial tumors. Moreover, the tumor displayed an extensive infiltrate by CD8+ T cells, and PD-L1 was expressed in the tumor immune microenvironment.

In the first-line setting, the results of this trial were pivotal for numerous reasons; Doxorubicin-Trabectedin is the first combination that has been proven to be more effective in terms of PFS, ORR and trend of OS compared with doxorubicin alone; moreover, it is clear that trials regarding soft tissue sarcoma should strive to be histology-driven.

Its combination with doxorubicin showed encouraging results in a phase II trial, leading to its approval...Previous premedication with dexamethasone and H1 antagonist was administered... Trabectedin plus olaratumab was a safe regimen, allowing full doses of both drugs in combination. Its toxicity and efficacy profiles seem favorable in this limited prospective series. Translational analyses are ongoing.

Our experience from a tertiary care center shows results similar to those reported in the literature. The immunogenicity and heterogeneity of soft tissue sarcomas pose a challenge to the treatment of soft tissue sarcomas, but they also allow a wide array of possible management solutions.